Expanding Cancer Screening: The Future of Blood-Based Testing
November 21st 2023Closing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.
Read More
Moonshot Cancer Initiative and MCED Consortium: Advancing Cancer Detection
November 14th 2023Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.
Read More
Latest Insights from the PATHFINDER Study: Cancer Detection Advancements
October 24th 2023Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.
Read More
Addressing Health Inequities in Cancer Screening: Challenges and Opportunities
September 29th 2023Explore critical issues surrounding health disparities in cancer screening, as discussed by experts, and the urgent need to bridge gaps in access, trust, and follow-up care for underserved populations.
Read More
Dr. Beer on the Immune-Related Adverse Events of Ipilimumab in mCRPC
May 16th 2014Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Read More
Dr. Beer on the Implications of the PREVAIL Study
February 3rd 2014Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.
Read More